MA30807B1 - Compositions pharmaceutiques. - Google Patents

Compositions pharmaceutiques.

Info

Publication number
MA30807B1
MA30807B1 MA31809A MA31809A MA30807B1 MA 30807 B1 MA30807 B1 MA 30807B1 MA 31809 A MA31809 A MA 31809A MA 31809 A MA31809 A MA 31809A MA 30807 B1 MA30807 B1 MA 30807B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
pellets
salt
produced
pharmaceutically acceptable
Prior art date
Application number
MA31809A
Other languages
English (en)
Inventor
Nathalie Bruneau
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37684496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30807(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30807B1 publication Critical patent/MA30807B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE, EN PARTICULIER DES CAPSULES, COMPRENANT DES GRANULÉS CONTENANT DU NILOTINIB OU UN SEL DE CELUI-CI, AINSI QU'AU MOINS UN EXCIPIENT PHARMACEUTIQUEMENT ACCEPTABLE. CES GRANULÉS PEUVENT ÊTRE PRODUITS PAR UN PROCÉDÉ DE GRANULATION PAR VOIE HUMIDE.
MA31809A 2006-09-27 2009-04-22 Compositions pharmaceutiques. MA30807B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06121371A EP1923053A1 (fr) 2006-09-27 2006-09-27 Composition pharmaceutique comprenant de la nilotinib ou son sel

Publications (1)

Publication Number Publication Date
MA30807B1 true MA30807B1 (fr) 2009-10-01

Family

ID=37684496

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31809A MA30807B1 (fr) 2006-09-27 2009-04-22 Compositions pharmaceutiques.

Country Status (34)

Country Link
US (2) US8293756B2 (fr)
EP (4) EP1923053A1 (fr)
JP (2) JP5567340B2 (fr)
KR (2) KR20090076931A (fr)
CN (2) CN104306350A (fr)
AR (1) AR062980A1 (fr)
AU (1) AU2007301977B2 (fr)
BR (1) BRPI0719438B1 (fr)
CA (1) CA2662571C (fr)
CL (1) CL2007002766A1 (fr)
CO (1) CO6160288A2 (fr)
CY (2) CY1117021T1 (fr)
DK (2) DK2068839T3 (fr)
ES (3) ES2556625T5 (fr)
FI (2) FI2068839T4 (fr)
HR (2) HRP20230753T3 (fr)
HU (2) HUE063083T2 (fr)
IL (1) IL197496A (fr)
JO (1) JO3757B1 (fr)
LT (1) LT3984528T (fr)
MA (1) MA30807B1 (fr)
MX (1) MX2009003184A (fr)
MY (1) MY148237A (fr)
NO (2) NO347404B1 (fr)
NZ (1) NZ575317A (fr)
PE (2) PE20081379A1 (fr)
PL (2) PL3984528T3 (fr)
PT (2) PT3984528T (fr)
RU (1) RU2469707C2 (fr)
SI (2) SI2068839T2 (fr)
TN (1) TN2009000093A1 (fr)
TW (3) TWI428333B (fr)
WO (1) WO2008037716A2 (fr)
ZA (1) ZA200901511B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1923053A1 (fr) * 2006-09-27 2008-05-21 Novartis AG Composition pharmaceutique comprenant de la nilotinib ou son sel
CA2775400A1 (fr) 2009-09-28 2011-03-31 Medizinische Universitat Wien Nouvelle utilisation des inhibiteurs de pdgf-beta
EP2490690A1 (fr) * 2009-10-23 2012-08-29 Novartis AG Procédé de traitement de troubles prolifératifs et d'autres états pathologiques à médiation par une activité kinase de bcr-abl, c-kit, ddr1, ddr2 ou pdgf-r
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2011CH01887A (fr) * 2011-06-02 2012-12-14
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
CN102321073A (zh) * 2011-08-12 2012-01-18 西安交通大学 一种尼罗替尼的制备方法
CN103889422A (zh) 2011-10-28 2014-06-25 诺华股份有限公司 治疗胃肠道间质瘤的方法
WO2013063003A1 (fr) 2011-10-28 2013-05-02 Novartis Ag Méthode de traitement des tumeurs stromales gastro-intestinales
US9301957B2 (en) 2011-11-14 2016-04-05 Novartis Ag Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
BR112014011518A2 (pt) * 2011-11-14 2017-05-16 Novartis Ag liberação imediata da formulação 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida
IN2014DN10801A (fr) 2012-07-11 2015-09-04 Novartis Ag
WO2014174496A1 (fr) 2013-04-25 2014-10-30 Ranbaxy Laboratories Limited Forme posologique orale solide de produit pharmaceutique à rétention gastrique de nilotinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
WO2016024289A2 (fr) 2014-08-11 2016-02-18 Sun Pharmaceutical Industries Ltd Nouveaux sels de nilotinib et leurs polymorphes
WO2016033304A1 (fr) * 2014-08-28 2016-03-03 Codexis, Inc. Dérivés d'imidazoyle anilide et procédés d'utilisation desdits dérivés
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US20200163962A1 (en) * 2016-03-17 2020-05-28 Sun Pharmaceutical Industries Ltd. Pharmaceutical composition of nilotinib
CN107582531B (zh) * 2016-07-06 2020-12-29 四川科伦药物研究院有限公司 一种利伐沙班固体制剂及其制备方法
CN107320460B (zh) * 2017-08-04 2020-11-03 北京化工大学 一种尼罗替尼口服纳米制剂及其制备方法
CN107441094B (zh) * 2017-08-08 2020-05-22 南方医科大学 尼罗替尼作为治疗登革病毒感染的药物及其制药用途
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
AU2019285066B2 (en) 2018-06-15 2024-06-13 Handa Pharmaceuticals, Inc. Kinase inhibitor salts and compositions thereof
EP4096791A1 (fr) 2020-01-31 2022-12-07 Nanocopoeia LLC Microparticules de nilotinib amorphe et leurs utilisations
IL297776A (en) 2020-04-30 2022-12-01 Nanocopoeia Llc Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib
JP7489849B2 (ja) * 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤
MX2023003556A (es) 2020-09-29 2023-06-13 Shenzhen Pharmacin Co Ltd Composiciones farmaceuticas.
US20240316044A1 (en) 2021-06-19 2024-09-26 Helm Ag Granulate composition comprising nilotinib
WO2023285981A1 (fr) * 2021-07-15 2023-01-19 Torrent Pharmaceuticals Limited Composition pharmaceutique liquide stable de nilotinib
EP4122452A1 (fr) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Composition pharmaceutique comprenant du nilotinib et son procédé de fabrication
EP4260848A1 (fr) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Composition pharmaceutique pour forme posologique solide contenant du nilotinib et son procédé de préparation
LU103368B1 (en) 2022-12-29 2024-11-04 Renata Pharmaceuticals Ireland Ltd Pharmaceutical suspension of nilotinib
WO2024194718A1 (fr) * 2023-03-22 2024-09-26 Unichem Laboratories Limited Composition pharmaceutique stable et son procédé de préparation
CN116854638A (zh) * 2023-06-05 2023-10-10 南华大学 一种含烷基链的氨基酸甲酯类化合物及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP3125221B2 (ja) * 1990-09-01 2001-01-15 大正製薬株式会社 ソファルコン含有固形製剤
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
DE69739802D1 (de) 1996-07-24 2010-04-22 Celgene Corp Substituierte 2-(2,6-Dioxopiperidine-3-yl)-phthalimide -1-oxoisoindoline und Verfahren zur Reduzierung des TNF-alpha Spiegels
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
FR2783421B1 (fr) * 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
UA72922C2 (uk) 1999-08-03 2005-05-16 Ліллі Айкос Ллк ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ З <font face="Symbol">b</font>-КАРБОЛІНОМ (ВАРІАНТИ) ТА СПОСІБ ЛІКУВАННЯ СЕКСУАЛЬНОЇ ДИСФУНКЦІЇ
WO2001041761A2 (fr) * 1999-12-08 2001-06-14 Pharmacia Corporation Compositions de valdecoxib
NZ519984A (en) 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
AU2003236947A1 (en) * 2002-06-07 2003-12-22 Ranbaxy Laboratories Limited Modified release, multiple unit drug delivery systems
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
SI1565258T1 (sl) * 2002-11-26 2012-04-30 Univ Gent Postopek in naprava za neprekinjeno mokro granulacijo materiala v prahu
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
ATE540671T1 (de) * 2003-08-04 2012-01-15 Bend Res Inc Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
TR200301553A1 (tr) 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
WO2005065653A1 (fr) * 2003-12-19 2005-07-21 E.I. Du Pont De Nemours And Company Enrobage intime d'ibuprofene avec des poloxameres afin d'ameliorer la dissolution aqueuse
WO2006013444A1 (fr) 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Preparations de compositions pharmaceutiques stables de nateglinide et procedes de preparation de celles-ci
JP4884975B2 (ja) * 2004-10-01 2012-02-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 微粒子含有組成物およびその製造方法
EP1830822A1 (fr) * 2004-12-24 2007-09-12 LEK Pharmaceuticals D.D. Composition pharmaceutique stable comprenant un substance active sous la forme d'une solution solide
CN101203224B (zh) * 2005-01-28 2010-11-03 诺瓦提斯公司 嘧啶基氨基苯甲酰胺在制备治疗对Tie-2激酶活性的调节有响应的疾病的药物中的用途
CN101160131A (zh) * 2005-02-25 2008-04-09 诺瓦提斯公司 Bcr-abl和raf抑制剂的药物组合产品
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
US20100038816A1 (en) * 2006-08-16 2010-02-18 Novartis Ag Method of making solid dispersions of highly crystalline therapeutic compounds
EP1923053A1 (fr) 2006-09-27 2008-05-21 Novartis AG Composition pharmaceutique comprenant de la nilotinib ou son sel

Also Published As

Publication number Publication date
PL2068839T5 (pl) 2023-01-30
DK2068839T3 (da) 2016-01-11
HRP20151383T1 (hr) 2016-01-15
NZ575317A (en) 2011-12-22
PL2068839T3 (pl) 2016-06-30
EP2068839B2 (fr) 2022-10-12
KR20140121903A (ko) 2014-10-16
EP3009128B1 (fr) 2023-07-05
ZA200901511B (en) 2010-02-24
JP2014065715A (ja) 2014-04-17
BRPI0719438A2 (pt) 2013-12-10
TWI540128B (zh) 2016-07-01
AU2007301977B2 (en) 2011-09-08
CN104306350A (zh) 2015-01-28
EP2068839B1 (fr) 2015-09-23
TW200821298A (en) 2008-05-16
PE20120626A1 (es) 2012-06-07
CN101516344A (zh) 2009-08-26
MX2009003184A (es) 2009-04-03
EP3984528B1 (fr) 2023-07-05
BRPI0719438B1 (pt) 2022-04-19
AU2007301977A1 (en) 2008-04-03
NO20091501L (no) 2009-04-24
CA2662571A1 (fr) 2008-04-03
PL3984528T3 (pl) 2023-08-28
PE20081379A1 (es) 2008-11-27
SI2068839T2 (sl) 2023-01-31
DK3984528T3 (da) 2023-07-31
JO3757B1 (ar) 2021-01-31
TWI428333B (zh) 2014-03-01
HRP20230753T3 (hr) 2023-10-27
ES2951547T3 (es) 2023-10-23
CL2007002766A1 (es) 2008-08-08
NO20220946A1 (no) 2009-04-24
HUE063083T2 (hu) 2023-12-28
TN2009000093A1 (en) 2010-08-19
ES2556625T5 (es) 2023-03-02
IL197496A0 (en) 2009-12-24
EP2068839A2 (fr) 2009-06-17
ES2957912T3 (es) 2024-01-29
HK1133193A1 (en) 2010-03-19
RU2009115782A (ru) 2010-11-10
NO346639B1 (no) 2022-11-07
HRP20151383T4 (hr) 2023-03-03
US20130023549A1 (en) 2013-01-24
IL197496A (en) 2016-04-21
US20100087463A1 (en) 2010-04-08
KR101598747B1 (ko) 2016-03-02
JP5567340B2 (ja) 2014-08-06
TW201418244A (zh) 2014-05-16
FI2068839T4 (fi) 2023-01-31
MY148237A (en) 2013-03-29
AR062980A1 (es) 2008-12-17
WO2008037716A3 (fr) 2008-07-17
TW201418245A (zh) 2014-05-16
CY1117021T1 (el) 2017-04-05
SI2068839T1 (sl) 2016-02-29
CA2662571C (fr) 2016-09-27
LT3984528T (lt) 2023-08-10
WO2008037716A2 (fr) 2008-04-03
CY1126116T1 (el) 2023-11-15
HUE028204T2 (en) 2016-12-28
PT3984528T (pt) 2023-08-07
CO6160288A2 (es) 2010-05-20
EP3009128A1 (fr) 2016-04-20
US8501760B2 (en) 2013-08-06
ES2556625T3 (es) 2016-01-19
JP2010504942A (ja) 2010-02-18
EP3984528A1 (fr) 2022-04-20
PT2068839E (pt) 2015-12-30
FI3984528T3 (fi) 2023-07-27
EP1923053A1 (fr) 2008-05-21
NO347404B1 (no) 2023-10-16
KR20090076931A (ko) 2009-07-13
US8293756B2 (en) 2012-10-23
RU2469707C2 (ru) 2012-12-20
SI3984528T1 (sl) 2023-09-29

Similar Documents

Publication Publication Date Title
MA30807B1 (fr) Compositions pharmaceutiques.
WO2007052289A3 (fr) Nouvelle composition de comprime dispersible
MA29816B1 (fr) Composes de benzimidazole thiophene
MA31898B1 (fr) Compositions pharmaceutiques
MA34286B1 (fr) Compositions pharmaceutiques et procédés pour les fabriquer
MA31684B1 (fr) Composition pharmaceutique contenant un antagoniste des canaux calciques de type dihydropyridine et son procédé de préparation
MA30765B1 (fr) Derives innovants du thiophene
TW200722100A (en) A therapeutic agent for a β related disorders
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l&#39;indolylmaleimide
WO2008017867A3 (fr) Composition orale solide antirétrovirale
ZA200806778B (en) N-Hydroxyacrylamide compounds
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
MA31445B1 (fr) Composition à libération modifiée comprenant un dérivé de somatostatine en microparticules
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
MA32275B1 (fr) Preparations orales et injectables de composes de tetracycline
MA33602B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l&#39;arthrite rhumatoïde, contenant du rébamipide
WO2008039351A3 (fr) Procédé de fabrication de comprimés contenant des agents de qualité pharmacologique
WO2008020314A3 (fr) Formulations de dosage stabilisantes à base de statine
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
EA201001108A1 (ru) Диспергируемые во рту таблетки, содержащие основание эсциталопрама, и способ их получения
WO2006060532A3 (fr) Formulations de benzoxazoles substitues
EA200900622A1 (ru) Фармацевтическая композиция, содержащая полиморфную форму 1 клопидогрела гидросульфата
UA95088C2 (ru) Композиция, которая содержит наночастички связанные с биосовместимым полимером противоракового агента и снижает аллопецию при химиотерапии, способ ее получения
UA95274C2 (ru) Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления
WO2007007182A3 (fr) Formes galeniques solides d&#39;agent antiepileptique